These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

916 related articles for article (PubMed ID: 17414590)

  • 41. Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
    Charpentier G; Halimi S;
    Diabetes Obes Metab; 2009 Sep; 11(9):844-54. PubMed ID: 19614944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
    Goldstein BJ; Pans M; Rubin CJ
    Clin Ther; 2003 Mar; 25(3):890-903. PubMed ID: 12852706
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Short-term intensive combined therapy with metformin, sagliptin and dapagliflozin for newly diagnosed type 2 diabetes: efficacy, weight control and safety].
    Xu Y; Wu P; Wen W; Chen H
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Nov; 39(11):1305-1311. PubMed ID: 31852646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
    Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
    Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.
    Derosa G; D'Angelo A; Romano D; Maffioli P
    Drug Des Devel Ther; 2017; 11():1481-1488. PubMed ID: 28553078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V; Rosenstock J; Patwardhan R; Salzman A
    JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RETRACTED: Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.
    Derosa G; Ragonesi PD; Carbone A; Fogari E; D'Angelo A; Cicero AF; Maffioli P
    Pharmacol Res; 2013 Jul; 73():20-6. PubMed ID: 23624419
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients.
    Derosa G; Putignano P; Bossi AC; Bonaventura A; Querci F; Franzetti IG; Guazzini B; Testori G; Fogari E; Maffioli P
    Eur J Pharmacol; 2011 Sep; 666(1-3):251-6. PubMed ID: 21645507
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus].
    Chen P; Huang Q; Xu XJ; Shao ZL; Huang LH; Yang XZ; Guo W; Li CM; Chen C
    Zhonghua Nei Ke Za Zhi; 2016 May; 55(5):349-54. PubMed ID: 27143183
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Usefulness of Diagnostic Panels Based on Circulating Adipocytokines/Regulatory Peptides, Renal Function Tests, Insulin Resistance Indicators and Lipid-Carbohydrate Metabolism Parameters in Diagnosis and Prognosis of Type 2 Diabetes Mellitus with Obesity.
    Komosinska-Vassev K; Gala O; Olczyk K; Jura-Półtorak A; Olczyk P
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32917052
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus.
    Hassan MH; Abd-Allah GM
    Pak J Pharm Sci; 2015 Sep; 28(5):1723-30. PubMed ID: 26408873
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatic insulin resistance affects the efficacy of metformin in patients with newly diagnosed type 2 diabetes: A Sub-Analysis of the MARCH trial.
    Cui R; Wei Y; Liu J; Wang G
    Diabetes Res Clin Pract; 2024 Aug; 214():111788. PubMed ID: 39032659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of glimepiride in Japanese type 2 diabetic subjects.
    Inukai K; Watanabe M; Nakashima Y; Sawa T; Takata N; Tanaka M; Kashiwabara H; Yokota K; Suzuki M; Kurihara S; Awata T; Katayama S
    Diabetes Res Clin Pract; 2005 Jun; 68(3):250-7. PubMed ID: 15936468
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
    Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of metformin on gut microbiota imbalance in patients with T2DM, and the value of probiotic supplementation.
    Li L; Chen Y; Tang Z; You Y; Guo Y; Liao Y
    Allergol Immunopathol (Madr); 2024; 52(4):84-90. PubMed ID: 38970270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.